source
- AstraZeneca to take rights to Dizal's lung cancer pill ZegfrovyAstraZeneca is set to pay Dizal Pharmaceutical, which it part-owns, $600 million upfront for worldwide development and sales rights to the lung cancer drug Zegfrovy. The UK pharma said Tuesday that…Endpoints · 16d ago↗ source
- In latest deal, Innovent seeds Spero's future beyond GSK-owned antibioticAfter partnering with four of the largest pharmaceutical companies over the past 18 months, Innovent Biologics is turning to a smaller partner for its next bet. An autoimmune drug candidate from th…Endpoints · 16d ago↗ source
- Former Akero team announces new I&I company, Avere, with China drugEverything around China biotech really does seem to be speeding up. On Tuesday, the former executive team behind Akero Therapeutics unveiled a new company, a pipeline drug from China and a reverse…